Highly potent, synthetically accessible prostratin analogs induce latent HIV expression in vitro and ex vivo
- 28 June 2013
- journal article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 110 (29) , 11698-11703
Abstract
Highly active antiretroviral therapy (HAART) decreases plasma viremia below the limits of detection in the majority of HIV-infected individuals, thus serving to slow disease progression. However, HAART targets only actively replicating virus and is unable to eliminate latently infected, resting CD4 + T cells. Such infected cells are potentially capable of reinitiating virus replication upon cessation of HAART, thus leading to viral rebound. Agents that would eliminate these reservoirs, when used in combination with HAART, could thus provide a strategy for the eradication of HIV. Prostratin is a preclinical candidate that induces HIV expression from latently infected CD4 + T cells, potentially leading to their elimination through a virus-induced cytopathic effect or host anti-HIV immunity. Here, we report the synthesis of a series of designed prostratin analogs and report in vitro and ex vivo studies of their activity relevant to induction of HIV expression. Members of this series are up to 100-fold more potent than the preclinical lead (prostratin) in binding to cell-free PKC, and in inducing HIV expression in a latently infected cell line and prostratin-like modulation of cell surface receptor expression in primary cells from HIV-negative donors. Significantly, selected members were also tested for HIV induction in resting CD4 + T cells isolated from infected individuals receiving HAART and were found to exhibit potent induction activity. These more potent agents and by extension related tunable analogs now accessible through the studies described herein should facilitate research and preclinical advancement of this strategy for HIV/AIDS eradication.Keywords
This publication has 30 references indexed in Scilit:
- Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitroNature Chemistry, 2012
- Bryostatin Modulates Latent HIV-1 Infection via PKC and AMPK Signaling but Inhibits Acute Infection in a Receptor Independent MannerPLOS ONE, 2010
- Immunotoxin Complementation of HAART to Deplete Persisting HIV-Infected Cell ReservoirsPLOS Pathogens, 2010
- Understanding HIV-1 latency provides clues for the eradication of long-term reservoirsNature Reviews Microbiology, 2009
- An Antibody-Recruiting Small Molecule That Targets HIV gp120Journal of the American Chemical Society, 2009
- Variability in Content of the Anti-AIDS Drug Candidate Prostratin in Samoan Populations of Homalanthus nutansJournal of Natural Products, 2008
- Short Communication: Activating Stimuli Enhance Immunotoxin-Mediated Killing of HIV-Infected MacrophagesAIDS Research and Human Retroviruses, 2008
- Practical Synthesis of Prostratin, DPP, and Their Analogs, Adjuvant Leads Against Latent HIVScience, 2008
- Expression of Latent HAART-Persistent HIV Type 1 Induced by Novel Cellular Activating AgentsAIDS Research and Human Retroviruses, 2004
- Transcriptional Regulation of the Gene Encoding the Human C-type Lectin Leukocyte Receptor AIM/CD69 and Functional Characterization of Its Tumor Necrosis Factor-α-responsive ElementsJournal of Biological Chemistry, 1995